These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 23599461)

  • 1. Preventing prejudice in genome profiling.
    Maruthappu M; Finlayson AE
    Science; 2013 Apr; 340(6130):273. PubMed ID: 23599461
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnostic cancer genome sequencing and the contribution of germline variants.
    Kilpivaara O; Aaltonen LA
    Science; 2013 Mar; 339(6127):1559-62. PubMed ID: 23539595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FASAY: a simple functional assay in yeast for identification of p53 mutation in tumors.
    Smardová J
    Neoplasma; 1999; 46(2):80-8. PubMed ID: 10466430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline TP53 mutations is common in patients with two early-onset primary malignancies.
    Chak BP; Chan ES; Tong JH; Leung AW; Cheng FW; Lam GK; Shing MM; Li CK; To KF
    Clin Genet; 2015 May; 87(5):499-501. PubMed ID: 25293557
    [No Abstract]   [Full Text] [Related]  

  • 5. Zoom-in array comparative genomic hybridization (aCGH) to detect germline rearrangements in cancer susceptibility genes.
    Staaf J; Borg A
    Methods Mol Biol; 2010; 653():221-35. PubMed ID: 20721746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Frequency of Germline BRCA1/2 Mutations.
    Maxwell KN; Domchek SM; Nathanson KL; Robson ME
    J Clin Oncol; 2016 Dec; 34(34):4183-4185. PubMed ID: 27551127
    [No Abstract]   [Full Text] [Related]  

  • 7. High-throughput oncogene mutation profiling in human cancer.
    Thomas RK; Baker AC; Debiasi RM; Winckler W; Laframboise T; Lin WM; Wang M; Feng W; Zander T; MacConaill L; Lee JC; Nicoletti R; Hatton C; Goyette M; Girard L; Majmudar K; Ziaugra L; Wong KK; Gabriel S; Beroukhim R; Peyton M; Barretina J; Dutt A; Emery C; Greulich H; Shah K; Sasaki H; Gazdar A; Minna J; Armstrong SA; Mellinghoff IK; Hodi FS; Dranoff G; Mischel PS; Cloughesy TF; Nelson SF; Liau LM; Mertz K; Rubin MA; Moch H; Loda M; Catalona W; Fletcher J; Signoretti S; Kaye F; Anderson KC; Demetri GD; Dummer R; Wagner S; Herlyn M; Sellers WR; Meyerson M; Garraway LA
    Nat Genet; 2007 Mar; 39(3):347-51. PubMed ID: 17293865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The human cancer genome project--one more misstep in the war on cancer.
    Gabor Miklos GL
    Nat Biotechnol; 2005 May; 23(5):535-7. PubMed ID: 15877064
    [No Abstract]   [Full Text] [Related]  

  • 9. Differential analysis between somatic mutation and germline variation profiles reveals cancer-related genes.
    Przytycki PF; Singh M
    Genome Med; 2017 Aug; 9(1):79. PubMed ID: 28841835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The challenge of using SNPs in the understanding and treatment of disease.
    Schifreen RS; Storts DR; Buller AM
    Biotechniques; 2002 Jun; Suppl():14-6, 18, 20-1. PubMed ID: 12083392
    [No Abstract]   [Full Text] [Related]  

  • 11. More Pitfalls Related to Next-generation Sequencing (NGS).
    Sorscher S
    Am J Clin Oncol; 2016 Aug; 39(4):424. PubMed ID: 27465427
    [No Abstract]   [Full Text] [Related]  

  • 12. How early to test for a cancer-causing germline mutation.
    Lynch HT; Lynch JF
    Cancer Genet Cytogenet; 2008 Jan; 180(1):87-8. PubMed ID: 18068543
    [No Abstract]   [Full Text] [Related]  

  • 13. Exploring the Link between the Germline and Somatic Genome in Cancer.
    Geeleher P; Huang RS
    Cancer Discov; 2017 Apr; 7(4):354-355. PubMed ID: 28373166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Critical parameters in clinical sequencing].
    Jordan B
    Med Sci (Paris); 2012 Jan; 28(1):109-11. PubMed ID: 22289839
    [No Abstract]   [Full Text] [Related]  

  • 15. Does a cost-effective approach for the determination of KRAS mutations maximize the patient's benefit in a clinical setting?
    Kobunai T; Watanabe T; Yamamoto Y; Fukusato T
    Pharmacogenomics; 2011 Mar; 12(3):307-8; author reply 309-10. PubMed ID: 21449668
    [No Abstract]   [Full Text] [Related]  

  • 16. A review on the Idylla platform: towards the assessment of actionable genomic alterations in one day.
    Uguen A; Troncone G
    J Clin Pathol; 2018 Sep; 71(9):757-762. PubMed ID: 29903742
    [No Abstract]   [Full Text] [Related]  

  • 17. [Molecular diagnostic techniques in oncogenetics].
    Beroud C
    Ann Med Interne (Paris); 2001 Sep; 152(5):326-31. PubMed ID: 11593145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of whole genome amplification for analysis of the p53 tumor suppressor gene in limited amounts of tumor samples.
    Hasmats J; Green H; Solnestam BW; Zajac P; Huss M; Orear C; Validire P; Bjursell M; Lundeberg J
    Biochem Biophys Res Commun; 2012 Aug; 425(2):379-83. PubMed ID: 22842464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating next-generation sequencing into clinical cancer diagnostics.
    Chan M; Lee CW; Wu M
    Expert Rev Mol Diagn; 2013 Sep; 13(7):647-50. PubMed ID: 24063391
    [No Abstract]   [Full Text] [Related]  

  • 20. Sex differences in cancer risk among germline p53 mutation carriers.
    Chompret A; Brugières L; Bonaïti-Pellié C; Feunteun J
    Br J Cancer; 2004 Aug; 91(3):603-4. PubMed ID: 15280910
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.